MedBiome News and Technology Updates / MedBiome licenses the MetaLab metaproteomic software

MedBiome licenses the MetaLab metaproteomic software

Published on: 05 February, 2020

MedBiome is pleased to announce that it has licensed the iMetaLab software platform from the University of Ottawa. iMetaLab (imetalab.ca) is a leading bioinformatics software for metaproteomics data analysis. MedBiome uses the iMetaLab software in combination with the RapidAIM assay to identify Precision Microbiome Therapeutics that change the composition of the human microbiome, promote the productions of specific metabolites by the human microbiome and for the stratification of patients based on their microbiome responses. MedBiome develops Precision Microbiome Therapeutics for Inflammatory Bowel Disease, Alzheimer's Disease, Chronic kidney disease and Colorectal cancer.

Innovations on human gut microbiome based drug discoveries

MedBiome focuses on the development of drugs that target the human microbiome. Our mission is to identify drugs that target the microbiome to improve human health.

MedBiome was launched in 2018 as the result of technologies developed at the University of Ottawa.

MedBiome is located in Ottawa, ON, Canada.

© 2019. MedBiome, Inc. All Rights Reserved.

Quick Links

Admin Access

  • Log In
MicroBiome Inc. LOGO